|[April 24, 2014]
Fresenius Kabi Introduces Lovo Cell Processing System
PARIS --(Business Wire)--
Fresenius Kabi, a global health care company that specializes in
life-saving medicines and technologies for infusion, transfusion and
clinical nutrition, today introduced its new Lovo cell-processing system
at the 2014 International Society for Cellular Therapy (ISCT) annual
Fresenius Kabi's Lovo is faster than traditional methods and automates the cell washing process. Lovo also offers the flexibility to process different cell lines. (Photo: Business Wire)
Lovo, which is designed for laboratories, is an automated "cell-washing"
system that removes supernatant from target cells and stores them in
viable media. Lovo automates the labor-intensive tasks of separation,
washing, platelet-depletion, fluid-exchange, and concentration of living
cells. The system includes single-use, pre-sterilized processing sets
for sterility assurance and is designed for use in a cGMP environment.
Lovo is currently undergoing evaluation for a broad range of cell
"We contiue to evaluate the Lovo system for multiple applications and
the interim data we are seeing for T-cells has been consistent with the
results to wash and concentrate white blood cells," said William Cork,
executive vice president and chief technology officer, Medical Devices
for Fresenius Kabi. "Fresenius Kabi will continue to test and evaluate
the use of the Lovo across a variety of cell therapy applications and
generate data this year on the operation, performance and usability of
In addition to the automated washing of white blood cells, Fresenius
Kabi is evaluating red blood cell and bone marrow processing
applications. Data presented at the 2013 ISCT demonstrated a 99 percent
reduction of supernatant in a 200 mL source product in less than seven
minutes. Lovo's output volume ranges from 50 ml to 5 L, depending on
cell type, cell concentration and source volume. The 2013 data were
collected using a prototype instrument.
Following its introduction at ISCT, Fresenius Kabi anticipates launching
Lovo in the United States in the second half of 2014. It will be
marketed to academic medical centers, biotech companies, blood centers
and facilities that process cells for clinical trials.
"Quality, consistency and speed are essential to institutions worldwide
that process cells for patient care and research," said Christian Hauer,
president, Medical Devices for Fresenius Kabi. "Lovo will automate
time-consuming manual processes for faster, easier and more consistent
results, and it offers the enhanced flexibility to process different
To learn more about Lovo, visit www.fresenius-kabi.us/lovo
or stop by the Fresenius Kabi booth (booth 71) during the 20th Annual
ISCT in Paris, which is being held April 23-26, 2014.
About Fresenius Kabi
Fresenius Kabi is a global health care company that specializes in
medicines and technologies for infusion, transfusion and clinical
nutrition. The company's products and services are used to help care for
critically and chronically ill patients.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140423006727/en/
[ Back To TMCnet.com's Homepage ]